Mesenchymal stem cell therapy for inflammatory bowel disease: A systematic review and meta-analysis

Inflammatory Bowel Diseases

Volumn 21, Issue 11, 2015, Pages 2696-2707

  Dave, Maneesh ^a   Mehta, Kathan ^b   Luther, Jay ^c   Baruah, Anushka ^d   Dietz, Allan B ^e   Faubion, William A ^e  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Jr Hospital of Cook County   (United States)

^e MAYO CLINIC   (United States)

Author keywords

adverse effects; efficacy; inflammatory bowel disease; mesenchymal stem cells; systematic review and meta analysis

Indexed keywords

ABDOMINAL ABSCESS; ADIPOSE DERIVED STEM CELL; ALLERGIC REACTION; ANXIETY DISORDER; CHOLECYSTITIS; CLINICAL PRACTICE; CROHN DISEASE; DIARRHEA; FEVER; HEALTH CARE COST; HUMAN; INFLAMMATORY BOWEL DISEASE; MESENCHYMAL STEM CELL TRANSPLANTATION; META ANALYSIS; PERIANAL ABSCESS; PRIORITY JOURNAL; PROCTALGIA; REVIEW; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; UTERUS MYOMA; ANIMAL; COLITIS, ULCERATIVE; GENE THERAPY; MOUSE; PROCEDURES;

ANIMALS; COLITIS, ULCERATIVE; CROHN DISEASE; GENETIC THERAPY; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MICE;

EID: 84945249500     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000543     Document Type: Review

References (86)

1. Dave M, Papadakis KA, Faubion Jr. W.A. Immunology of inflammatory bowel disease and molecular targets for biologics. Gastroenterol Clin North Am. 2014;43:405-424.
2. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369:711-721.
3. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699-710.
4. Poggioli G, Pierangeli F, Laureti S, et al. Review article: indication and type of surgery in Crohn's disease. Aliment Pharmacol Ther. 2002;16 (suppl 4):59-64.
5. Nicholls RJ. Review article: ulcerative colitis-surgical indications and treatment. Aliment Pharmacol Ther. 2002;16(suppl 4):25-28.
6. van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-Dumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129-135.
7. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
8. Jilani NZ, Akobeng AK. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
9. Colombel JF, Sandborn WJ, Rutgeerts P et al. Gastroenterology. 2007;132:52-65. J Pediatr Gastroenterol Nutr. 2008;46:226-227.
10. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;357:228-238.
11. O'Donoghue DP, Dawson AM, Powell-Duck J, et al. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet. 1978;2:955-957.
12. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-Derm, randomized, double-blind study. N Engl J Med. 1980;302:981-987.
13. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. Canadian inflammatory bowel disease study group. N Engl J Med. 1994;331:836-841.
14. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-Dosevere ulcerative colitis. Gastroenterology. 2014;146:85-95; quiz e14-5.
15. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392-400 e3.
16. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
17. Dave M, Purohit T, Razonable R, et al. Opportunistic infections due to inflammatory bowel disease therapy. Inflamm Bowel Dis. 2014;20:196-212.
18. Singh S, Kumar N, Loftus EV Jr, et al. Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics. Inflamm Bowel Dis. 2013;19:864-872.
19. Dulai PS, Siegel CA. The risk of malignancy associated with the Use of Biological Agents in patients with inflammatory bowel disease. Gastroenterol Clin North Am. 2014;43:525-541.
20. Armstrong L, Lako M, Buckley N, et al. Editorial: our top 10 developments in stem cell biology over the last 30 years. Stem Cells. 2012;30:2-9.
21. Muller FJ, Laurent LC, Kostka D, et al. Regulatory networks define phenotypic classes of human stem cell lines. Nature. 2008;455:401-405.
22. Keller G. Embryonic stem cell differentiation: emergence of a new era in biology and medicine. Genes Dev. 2005;19:1129-1155.
23. Korbling M, Estrov Z. Adult stem cells for tissue repair-A new therapeutic concept? N Engl J Med. 2003;349:570-582.
24. Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol. 2006;6:93-106.
25. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813-1826.
26. Garcia-Bosch O, Ricart E, Panes J. Review article: stem cell therapies for inflammatory bowel disease-efficacy and safety. Aliment Pharmacol Ther. 2010;32:939-952.
27. Hawkey CJ. Stem cells as treatment in inflammatory bowel disease. Dig Dis. 2012;30(suppl 3):134-139.
28. Koo BK, Clevers H. Stem cells marked by the R-spondin receptor LGR5. Gastroenterology. 2014;147:289-302.
29. Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol. 2007;213:341-347.
30. Kern S, Eichler H, Stoeve J, et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006;24:1294-1301.
31. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-147.
32. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997;276:71-74.
33. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-317.
34. Gonzalez-Rey E, Anderson P, Gonzalez MA, et al. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut. 2009;58:929-939.
35. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002;30:42-48.
36. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99:3838-3843.
37. English K. Mechanisms of mesenchymal stromal cell immunomodulation. Immunol Cell Biol. 2013;91:19-26.
38. Liu H, Liu S, Li Y, et al. The role of SDF-1-CXCR4/CXCR7 axis in the therapeutic effects of hypoxia-preconditioned mesenchymal stem cells for renal ischemia/reperfusion injury. PLoS One. 2012;7:e34608.
39. Sasaki M, Abe R, Fujita Y, et al. Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. J Immunol. 2008;180:2581-2587.
40. Qiu Y, Marquez-Curtis LA, Janowska-Wieczorek A. Mesenchymal stromal cells derived from umbilical cord blood migrate in response to complement C1q. Cytotherapy. 2012;14:285-295.
41. Ponte AL, Marais E, Gallay N, et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells. 2007;25:1737-1745.
42. Ren G, Zhang L, Zhao X, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008;2:141-150.
43. Krampera M, Cosmi L, Angeli R, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006;24:386-398.
44. Ge W, Jiang J, Arp J, et al. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation. 2010;90: 1312-1320.
45. Brown JM, Nemeth K, Kushnir-Sukhov NM, et al. Bone marrow stromal cells inhibit mast cell function via a COX2-dependent mechanism. Clin Exp Allergy. 2011;41:526-534.
46. Anderson P, Souza-Moreira L, Morell M, et al. Adipose-derived mesenchymal stromal cells induce immunomodulatory macrophages which protect from experimental colitis and sepsis. Gut. 2013;62:1131-1141.
47. English K, Barry FP, Mahon BP. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol Lett. 2008;115:50-58.
48. Djouad F, Charbonnier LM, Bouffi C, et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells. 2007;25:2025-2032.
49. Nauta AJ, Kruisselbrink AB, Lurvink E, et al. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocytederived dendritic cells. J Immunol. 2006;177:2080-2087.
50. Zhang B, Liu R, Shi D, et al. Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood. 2009;113:46-57.
51. Li YP, Paczesny S, Lauret E, et al. Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway. J Immunol. 2008;180:1598-1608.
52. Akiyama K, Chen C, Wang D, et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell. 2012;10:544-555.
53. Augello A, Tasso R, Negrini SM, et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol. 2005;35:1482-1490.
54. Sioud M. New insights into mesenchymal stromal cell-mediated T-cell suppression through galectins. Scand J Immunol. 2011;73:79-84.
55. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-269, W64.
56. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Volume 2014. London, UK: The Cochrane Collaboration; 2011.
57. Leeflang MM, Deeks JJ, Gatsonis C, et al. Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008;149:889-897.
58. Freeman MT, Tukey JW. Transformations related to the angular and the square root. Ann Math Stat. 1950;21:607-611.
59. DerSimonian R, Laird N. Meta-Analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
60. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-Analyses. BMJ. 2003;327:557-560.
61. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 7. Rating the quality of evidence-inconsistency. J Clin Epidemiol. 2011;64:1294-1302.
62. Team RC. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2013.
63. Schwarzer G. Meta: General Package for Meta-Analysis. R Package Version 4.1-0. Vienna, Austria: R Foundation, 2015.
64. Herreros MD, Garcia-Arranz M, Guadalajara H, et al. Autologous expanded adipose-derived stem cells for the treatment of complex cryptoglandular perianal fistulas: a phase III randomized clinical trial (FATT 1: fistula Advanced Therapy Trial 1) and long-Derm evaluation. Dis Colon Rectum. 2012;55:762-772.
65. Garcia-Olmo D, Garcia-Arranz M, Garcia LG, et al. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn's disease: a new cell-based therapy. Int J Colorectal Dis. 2003; 18:451-454.
66. Garcia-Olmo D, Garcia-Arranz M, Herreros D, et al. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005;48:1416-1423.
67. Cirocchi R, Farinella E, La Mura F, et al. Fibrin glue in the treatment of anal fistula: a systematic review. Ann Surg Innov Res. 2009;3:12.
68. Cirocchi R, Santoro A, Trastulli S, et al. Meta-Analysis of fibrin glue versus surgery for treatment of fistula-in-Ano. Ann Ital Chir. 2010;81:349-356.
69. Garcia-Olmo D, Herreros D, Pascual I, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum. 2009;52:79-86.
70. Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut. 2011;60:788-798.
71. de la Portilla F, Alba F, Garcia-Olmo D, et al. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis. 2013;28:313-323.
72. Cho YB, Lee WY, Park KJ, et al. Autologous adipose tissue-derived stem cells for the treatment of Crohn's fistula: a phase I clinical study. Cell Transplant. 2013;22:279-285.
73. Lee WY, Park KJ, Cho YB, et al. Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn's fistula. Stem Cells. 2013;31:2575-2581.
74. Cho YB, Park KJ, Yoon SN, et al. Long-Derm results of adipose-derived stem cell therapy for the treatment of Crohn's fistula. Stem Cells Transl Med. 2015;4:532-537.
75. Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis. 2010;4:63-101.
76. Onken JGD, Hanson J, Pandak M, et al. Sucessful outpatient treatment of refractory Cron's disease using adult mesenchymal stem cells. American College of Gastroenterology Annual Meeting 2006; Las Vegas, NV.
77. Duijvestein M, Vos AC, Roelofs H, et al. Autologous bone marrowderived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut. 2010;59:1662-1669.
78. Lazebnik LB, Konopliannikov AG, Kniazev OV, et al. Use of allogeneic mesenchymal stem cells in the treatment of intestinal inflammatory diseases [in Russian]. Ter Arkh. 2010;82:38-43.
79. Liang J, Zhang H, Wang D, et al. Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel disease. Gut. 2012;61:468-469.
80. Forbes GM, Sturm MJ, Leong RW, et al. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. Clin Gastroenterol Hepatol. 2014;12:64-71.
81. Martin PJU, Uberti JP, Soiffer RJ, et al. Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: Results of a randomized, placebo-controlled, multicenter phase III trial in GVHD. Biol Blood Marrow Transplant. 2010;16:169-170.
82. Galipeau J. The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mesenchymal stromal cells in steroidresistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy. 2013;15:2-8.
83. Duijvestein M, Wildenberg ME, Welling MM, et al. Pretreatment with interferon-gamma enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells. 2011;29:1549-1558.
84. Kim HS, Shin TH, Lee BC, et al. Human umbilical cord blood mesenchymal stem cells reduce colitis in mice by activating NOD2 signaling to COX2. Gastroenterology. 2013;145:1392-1403 e1-8.
85. Ankrum JA, Dastidar RG, Ong JF, et al. Performance-enhanced mesenchymal stem cells via intracellular delivery of steroids. Sci Rep. 2014;4:4645.
86. Dave M, Hayashi Y, Gajdos GB, et al. Stem cells for murine interstitial cells of cajal suppress cellular immunity and colitis via prostaglandin E2 secretion. Gastroenterology. 2015;148:978-990.